Form 4: Lyra Therapeutics Director C. Ann Merrifield Reports Acquisition of 32,000 Restricted Stock Units

Director C. Ann Merrifield reports the acquisition of 32,000 Restricted Stock Units (RSUs) in Lyra Therapeutics, Inc. on May 14, 2025.

Summary

• C. Ann Merrifield, a director of Lyra Therapeutics, Inc., filed a Form 4 to report changes in beneficial ownership.
• On May 14, 2025, Merrifield acquired 32,000 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Lyra Therapeutics' common stock.
• The RSUs will vest 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026, or (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.
• Following the transaction, Merrifield directly owns 32,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of RSUs, which can be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon future events, including the company's annual meeting date, the passage of time, or a change in control.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the holdings of a Lyra Therapeutics director.

Stakeholder Impact

• The acquisition of RSUs by a director could positively influence shareholder sentiment.

Key Dates

Keywords

Lyra Therapeutics, Form 4, Restricted Stock Units, RSU, Beneficial Ownership, Director, Merrifield, LYRA